About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, October 26th, 2017

The QualityStocks
Daily Stock List


iAnthus Capital Holdings, Inc. (ITHUF)

MarketWatch, InvestorsHub, Daily Marijuana Observer, Stockhouse, and OTC Markets reported on iAnthus Capital Holdings, Inc. (ITHUF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

iAnthus Capital Holdings, Inc. is a provider of capital investment and management services to licensed cannabis cultivators, processors, and dispensaries across the United States. The Company, through its 100 percent owned subsidiary, iAnthus Capital Management, LLC, delivers a total solution for financing and managing these enterprises. iAnthus supports a diversified portfolio of cannabis industry investments. iAnthus Capital Holdings has its head office in New York City. In addition, it has an office in Toronto, Ontario.

The Company provides a unique combination of capital and practical operating and management expertise. Entrepreneurs with decades of experience in investment banking, corporate finance, law, and healthcare services founded iAnthus Capital Holdings. iAnthus remains hands-on with its investments. It works with its partners to optimize opportunities, overcome hurdles, as well as maximize value.

iAnthus creates agreements that establish valuable partnerships. The Company has developed strategic partnerships with best-in-class industry-sector leaders in dispensary operations, commercial-scale cannabis cultivation, regulatory law, and the science of cannabis product formulation and testing.

iAnthus applies meticulous analysis to determine the very best business prospects in each market throughout the United States. The Company’s current portfolio includes Grassroots Vermont; Mayflower Medicinals, Inc.; Organix, Breckenridge Colorado; and R. Greenleaf Organics.

iAnthus Capital Holdings announced in March of this year that construction commenced on a state-of-the-art cannabis cultivation and processing facility in Holliston, Massachusetts for the benefit of Mayflower Medicinals, Inc. Mayflower is a Massachusetts non-profit Registered Marijuana Dispensary (RMD) license holder affiliated with iAnthus.

This past August, iAnthus provided an update on existing operations and strategic partnerships. In Q2 the Company signed a Letter of Intent (LOI) to acquire 100 percent of Citiva NY and Citiva USA for US$18.0 million; US$14.4 million in stock, US$3.6 million in cash. This acquisition provides iAnthus Capital exposure to one of the nation's largest markets, with a state-wide population of 20 million people. Citiva was granted dispensary locations in two New York City boroughs, Brooklyn and Staten Island, plus Dutchess County and Chemung County.

This month, iAnthus Capital Holdings announced that it purchased 2,925,003 Class B Shares of GrowHealthy Holdings, LLC for a total purchase price of US$3.0 million pursuant to a Class B Share Purchase Agreement. The Preferred Share Purchase represents roughly 6.1 percent of the issued and outstanding equity shares of GrowHealthy. Furthermore, iAnthus continues to engage in exclusive discussions with GrowHealthy and its affiliated Florida entities regarding a further strategic relationship.

iAnthus Capital Holdings, Inc. (ITHUF), closed Thursday's trading session at $1.44, down 0.69%, on 625,155 volume with 264 trades. The average volume for the last 60 days is 55,243 and the stock's 52-week low/high is $1.4108/$2.7953.

United Cannabis Corp. (CNAB)

Actual Gains, Broad Street, TopPennyStockMovers, OTCBB Journal, StocksImpossible, Cannabis Financial Network News, PricelessPennyStocks, PennyStockRumors, Stockgoodies, Promotion Stock Secrets, Wealth Insider Alert, Wall Street Mover, Market Intelligence Center Alert, Marketbeat, StreetAuthority Daily, Money Map Press, MyBestStockAlerts, and Wall Street Wolves reported on United Cannabis Corp. (CNAB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

United Cannabis Corp.’s dedication is to the development of phyto-therapeutic based products supported by patented technologies for the pharmaceutical, medical, and industrial markets. The Company formed to provide leadership in the medical cannabis industry. This is through providing patient driven solutions intent on improving biomedical and pharmaceutical pursuits using cannabis-based research, products, and services. A biotechnology enterprise, the Company is the creator of Prana Bio Nutrient Medicinals. United Cannabis is based in Denver, Colorado.

United Cannabis provides consulting services, proprietary products, and licenses its intellectual property (IP) to businesses in the cannabis industry. The Company owns distinct IP relating to the legalized growth, production, manufacture, marketing, management, use and distribution of medical and recreational marijuana and marijuana infused products. It has established affiliate relationships with Harborside Health Center of California, Prana Bio Nutrient Medicinals, Bubbleman, Blue River, and Cannabinoid Research & Development (CRD).

The United States Patent and Trademark Office (USPTO) has issued US Patent #9730911, granting exclusive rights to United Cannabis’ proprietary formulations based on compounds extracted from cannabis plant materials. More precisely, it is the composition of matter regarding the use of phytocannabinoids, cannabinoids, and specific terpene profiles in liquid form. This composition of matter patent provides protection for the Company’s proprietary formulations.

United Cannabis’ A.C.T. Now Program and Prana Bio Nutrient Medicinals provide a comprehensive solution designed to allow physicians and patients to implement and monitor effective therapy protocols. Prana Bio Nutrient Medicinals is a total, full spectrum cannabinoid system. It uses the whole cannabis plant through controlling specific cannabinoid ratios, accurate dosing, and numerous non-abrasive delivery methods.

The A.C.T. Now program provides affordable patient driven programs with limitless combinations of cannabinoid-based products. Moreover, it provides nutritional recommendations to help patients suffering from chronic pain, opiate dependency, inflammation, glaucoma, PTSD, neuropathy, multiple sclerosis, fibromyalgia, Crohn’s, IBS, seizures, epilepsy, paralysis, autoimmune, autism, tumors, HIV/AIDS, and many kinds of cancer.

Prana Bio Nutrient Medicinal products provide patients a way to mix/match cannabinoids for therapeutic purposes. These products are licensed to regulated marijuana dispensaries. The Company employs an infusion process using select fatty acids, lipids, and specific combinations of cannabis derived terpenes to increase bioavailability.

In July 2017, United Cannabis announced the acquisition of a majority share of Prana Therapeutics, Inc. (PTI). Prana is a clinical stage biotechnology company developing Polymolecular Botanical therapeutics for the oncology, neurology, and orthopedic markets. Prana concentrates on developing targeted therapeutics for the prevention of the negative side effects of chemotherapy, management of rheumatoid arthritis, and treatment of brain cancer.

This month, United Cannabis announced that Jamaica's Ministry of Health registered the Company’s Prana CBD-Infused Water as a medicinal cannabis product. The Prana Water will be manufactured and distributed by United Cannabis’ Jamaican subsidiary, Cannabinoid Research & Development Limited (CRD).

CRD has commenced preliminary work to initiate production of other United Cannabis products in Jamaica. This includes its Prana P5 Hemp Bio Nutrient Capsules, Aromatherapy Roll-On, as well as Sublingual Drops.

United Cannabis Corp. (CNAB), closed Thursday's trading session at $0.66, up 2.33%, on 57,177 volume with 77 trades. The average volume for the last 60 days is 101,130 and the stock's 52-week low/high is $0.535/$3.35.

Triumph Gold Corp. (NFRGF)

OTC Markets, Stockhouse, InvestorsHub, MarketWatch, TradingView, The Street, and Awesome Penny Stocks reported on Triumph Gold Corp. (NFRGF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Triumph Gold Corp. is a precious metals exploration and development company listed on the OTC Markets Group’s OTCQB. The Company concentrates on creating value via the advancement of the district scale Freegold Mountain project in the Yukon (100 percent owned). Triumph Gold has a leadership team with a collective history of exploration success and capital raising ability. The Company has its corporate office in Vancouver, British Columbia.

The Freegold Mountain project is in the Dawson Range. It encompasses a highly prospective section of the Big Creek fault zone. The Freegold Mountain project has three significant mineral deposits. This includes the Nucleus Au deposit, the Revenue Cu-Au-Mo-Ag deposit, as well as the Tinta Hill poly-metallic vein system. It also has many other gold showings.

Since Triumph Gold acquired the Freegold Mountain property in 2006, greater than 20 mineralized zones have been identified. Moreover, NI 43-101 (National Instrument 43-101) resources have been delineated at the Revenue and Nucleus porphyry deposits and the Tinta Hill high-grade poly-metallic vein deposit.

Triumph Gold also has its Tad/Toro Project. This project is 6,474 hectares. It is situated on Hayes Creek, within the Dawson Range of central Yukon, 100 km northwest of Carmacks, 177 km by road from Whitehorse, Yukon Territory. The property is in the Whitehorse Mining District.

In addition, the Company has its Severance Property. It is in the Klotassin River valley, 125 km west of Carmacks, Yukon. The property comprises 30 Quartz Claims staked in accordance with the Yukon Quartz Mining Act in the Whitehorse Mining District.

Last month, Triumph Gold announced the completion of its 2017 field season. The 2017 exploration campaign centered on its Freegold Mountain property. Work on the property included 35 diamond drill holes totaling 12,904 meters in the Revenue and Nucleus areas, more than 600 meters of trenching, and the collection of 993 soil samples at Tinta Hill, as well as reconnaissance work on a dozen other showings and prospects.

In addition, Triumph Gold geologists conducted reconnaissance mapping and sampling on the Company’s 100 percent owned Severance (YT), Tad/Toro (YT), and Andalusite Peak (BC) properties.

Last week, Triumph Gold announced that diamond drilling along the relatively underexplored eastern margin of the Revenue diatreme was rewarded with manifold intersections of copper, gold, silver +/- molybdenum mineralization. Recent geological reviews of mineralization in the Revenue area, helped by development of a 3D geological model of the 1,300 X 400 meter elliptical Revenue diatreme, targeted the eastern portion of the diatreme as most prospective for gold and copper mineralization. The design of the 2017 exploration program at Revenue was to test the eastern area with five drill holes totaling 2,032 meters.

Triumph Gold Corp. (NFRGF), closed Thursday's trading session at $0.22, down 8.49%, on 16,500 volume with 7 trades. The average volume for the last 60 days is 41,553 and the stock's 52-week low/high is $0.1286/$0.4633.

InnerScope Hearing Technologies, Inc. (INND)

InvestorsHub, Front Page Stocks, YCharts, Stockhouse, Stockopedia, and MarketWatch reported on InnerScope Hearing Technologies, Inc. (INND), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

InnerScope Hearing Technologies, Inc. is a technology driven enterprise with highly scalable B2B (Business-to-Business) and B2C (Business-to-Consumer) solutions. The Company has plans on opening, operating, and expanding a chain of audiological and retail hearing device clinics. Headquartered in Roseville, California, InnerScope Hearing Technologies lists on the OTC Markets Group’s OTCQB. The Company incorporated in June of 2012.

Last month, InnerScope Advertising Agency, Inc. announced its name change to InnerScope Hearing Technologies, Inc. This change was completed and approved by FINRA (Financial Industry Regulatory Authority). The change was effective September 18, 2017. InnerScope continues trading under the OTCQB ticker symbol: INND.

InnerScope’s updated business plan is to scale its infrastructure to develop and deploy a revenue eco-system strategy. This includes expanding the revenue model to other major sectors of the international hearing industry. It recently announced plans to acquire AUDserv, Inc.

InnerScope will create seven separate revenue generating divisions. The Company said that each division will generate revenue and be positioned for growth, thereby increasing InnerScope’s market penetration.

InnerScope provides a B2B SaaS (Software as a Service) based Patient Management System (PMS) software program. The design of this is to improve operations and communication with patients. In addition, the Company offers a Buying Group experience for audiology practices. This enables owners to reduce product costs and grow their margins.

Furthermore, InnerScope Hearing Technologies will compete in the DTC (Direct-to-Consumer) markets with its own line of "Hearables," and "Wearables" and cutting-edge Apps on the iOS and Android markets. In essence, the Company’s corporate mission isto innovate and deploy products and services on a scalable platform for the 360-plus million people around the Global Suffering from Hearing Impairment to create an Eco-System around the Company.

This month, InnerScope Hearing Technologies announced that it is entering into a supply and distribution agreement with Blue-Gear, Inc. This agreement is for global rights of Blue-Gear's Personal Sound Amplifier Products (PSAP). Blue-Gear's technical team will also be working with InnerScope Hearing Technologies employees to develop its own line of PSAP devices for worldwide distribution.

Additionally, this month, InnerScope announced its preferred vendor status with Samplified International BV. Samplified's U.S. subsidiary, Samplified-Audio LLC (Samplified US), headquartered in Boulder, Colorado, was recently announced the winner of the National Science Foundation's "National Hearables Challenge" for its Clementine Wear Audio Software Platform.

Samplified has developed "SnowOwl." This is its initial product utilizing the Clementine Wear platform. SnowOwl is a programmable audio companion for personalized sound experience in any situation. SnowOwl is the first hearable and wearable product with Clementine Wear built inside.

InnerScope Hearing Technologies, Inc. (INND), closed Thursday's trading session at $0.27, up 150.00%, on 1,085 volume with 2 trades. The average volume for the last 60 days is 5,264 and the stock's 52-week low/high is $0.047/$1.50.

Provectus Biopharmaceuticals, Inc. (PVCT)

StreetAuthorityDaily, TheMicrocapNews, Streetwise Reports, AllPennyStocks, Stock News Now, Seeking Alpha, TopPennyStockMovers, StreetInsider, The Street, TopStockAnalysts, plrinvest, Investors Underground, Real Pennies, PennyStocks24, Club Penny Stocks Network, and Wise Alerts reported previously on Provectus Biopharmaceuticals, Inc. (PVCT), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Provectus Biopharmaceuticals, Inc. is a clinical-stage oncology and dermatology biopharmaceutical company. It is developing new therapies for the treatment of solid tumor cancers and dermatologic diseases. The Company’s investigational oncology drug is PV-10. PV-10 is an oncolytic immunotherapy enrolling patients in Phase 3 clinical trials for metastatic melanoma. Provectus Biopharmaceuticals is based in Knoxville, Tennessee.

PV-10 is an ablative immunotherapy under investigation in solid tumor cancers. PH-10 is a topical investigational drug for dermatology. It is undergoing clinical testing for psoriasis and atopic dermatitis.

Provectus Pharmaceuticals completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. The intention of PV-10 is to kill only diseased cells upon injection into tumors. The Company has received orphan drug designations from the Food and Drug Administration (FDA) for its melanoma and hepatocellular carcinoma indications.

PV-10 is a 10 percent solution of small molecule and halogenated xanthene Rose Bengal. It is administered by way of direct injection into solid tumor cancers, such as melanoma, liver, and breast. It is not designed to rely on a single pathway, receptor or antigen to work; and there is no known resistance.

Pertaining to PH-10 for psoriasis and atopic dermatitis, a mechanism of action study is underway to measure the clinical and cellular response to PH-10's active investigational agent. A total of 226 subjects have been treated with PH-10 in Phase 1 or Phase 2 Clinical Trials.

Last week, Provectus Biopharmaceuticals announced that results from its continuing Phase 1b/2 study of IL PV-10 in combination with KEYTRUDA® (pembrolizumab), Merck’s systemic anti-PD-1 (programmed death receptor-1) antibody agent, were presented at the Society for Melanoma Research 2017 Congress, which took place in Brisbane, Australia from October 18-21.

IL injection of PV-10 induces immunogenic cell death that results in tumor-specific reactivity in circulating CD8+ T cells. There was a 50 percent overall objective response rate; 10 percent complete response. Adverse events were consistent with established patterns for each drug, and no unexpected toxicities were observed.

This week, Provectus Biopharmaceuticals announced that results from a Provectus-sponsored study to understand the daily life experiences of patients with locally advanced cutaneous melanoma were presented at the International Society for Quality of Life Research (ISOQOL) 24th Annual Conference in Philadelphia, Pennsylvania from October 18-21, 2017. Patient perceptions of their experiences related to this kind of melanoma are not well understood.

Mr. Dominic Rodrigues, Chairman of Provectus Pharmaceuticals’ Board of Directors, said, “These elicitation study data of patient-reported assessments of disease symptoms and quality of life show that patients afflicted with locally advanced cutaneous melanoma suffer important emotional impacts, presumably because they see their disease on a continuous basis. Intralesional therapy in general, and intralesional PV-10 in particular, may shrink or eliminate these patients’ accessible and visible tumors.

Provectus Biopharmaceuticals, Inc. (PVCT), closed Thursday's trading session at $0.0387, down 3.01%, on 255,881 volume with 30 trades. The average volume for the last 60 days is 546,194 and the stock's 52-week low/high is $0.011/$0.0679.

RespireRx Pharmaceuticals, Inc. (RSPI)

MarketWatch, InvestorsHub, Marketwired, and Barchart reported on RespireRx Pharmaceuticals, Inc. (RSPI), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Established in 1987, RespireRx Pharmaceuticals, Inc. is a leader in the development of medicines for respiratory disorders. These disorders include sleep apneas and drug-induced respiratory depression. The Company previously went by the name Cortex Pharmaceuticals, Inc. It changed its name to RespireRx Pharmaceuticals, Inc. in December 2015. RespireRx Pharmaceuticals is headquartered in Glen Rock, New Jersey.

The Company has filed more than 400 patents in the U.S. and offshore that claim composition of matter, use, formulation, dosage, and mechanism of action. Use claims include treating sleep apnea and preventing or rescuing drug-induced respiratory depression, as well as for improving memory and cognition, treating schizophrenia and other central nervous system indications.

RespireRx’s pharmaceutical candidates in development are derived from two platforms. One platform is the class of compounds called cannabinoids. This includes, in particular, Dronabinol.

Dronabinol (D9-THC, D9-tetrahydrocannabinol) is an oral capsule drug product. It is undergoing testing for clinical efficacy in patients with obstructive sleep apnea (OSA). Under a license agreement with the University of Illinois, RespireRx Pharmaceuticals has rights to patents claiming the use of cannabinoids for the treatment of sleep-related breathing disorders.

Dronabinol (D9-THC) is a generic, orally active cannabinoid. It has been shown to act at CB1 & CB2 receptors on neurons to stabilize respiratory patterns and augment upper airway muscles. Two Phase 2 clinical trials have been completed. Both have demonstrated substantial reductions in sleep apnea produced by dronabinol.

The other platform of medicines undergoing development by the Company is a class of proprietary compounds called ampakines. These act to enhance the actions of the excitatory neurotransmitter glutamate at AMPA glutamate receptor sites in the brain. A number of ampakines, in oral and injectable form, are undergoing development by RespireRx Pharmaceuticals for the treatment of an array of breathing disorders.

RespireRx announced positive results in December 2016 of the PACE (Pharmacotherapy of Apnea by Cannabimimetic Enhancement) trial conducted by Dr. David Carley and colleagues at the University of Illinois at Chicago and Northwestern University. The PACE trial is a Phase 2B study of dronabinol for the treatment of obstructive sleep apnea (OSA).

RespireRx stated that the PACE trial clearly demonstrates that dronabinol considerably improves the primary outcome measures of Apnea Hypopnea Index (AHI), daytime sleepiness as measured by the Epworth Sleepiness Scale (ESS) and overall patient satisfaction as measured by the Treatment Satisfaction Questionnaire for Medications (TSQM).

RespireRx Pharmaceuticals, Inc. (RSPI), closed Thursday's trading session at $0.80, even for the day, on 3 volume with 1 trade. The average volume for the last 60 days is 1,282 and the stock's 52-week low/high is $0.80/$4.40.


Marketbeat, BabyBulls, SmallCapVoice, Innovative Marketing, Zacks, and TopPennyStockMovers reported on ULURU, Inc. (ULUR), and today we report on the Company, here at the QualityStocks Daily Newsletter.

ULURU, Inc. is a specialty pharmaceutical company focusing on the development of a portfolio of wound management and oral care products. This is to provide patients and consumers improved clinical outcomes via controlled delivery using the Company’s unique Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. ULURU is headquartered in Addison, Texas.

ULURU’s business strategy is to develop and commercialize a customer-centered portfolio of inventive wound care products to treat the different phases of wound healing. In addition, the Company’s strategy involves developing the oral-transmucosal technology and producing revenues through many licensing agreements.

ULURU has its OraDisc™A product. It developed OraDisc™ A, a novel mucoadhesive, water-erodible disc incorporating 2mg of amlexanox, for the treatment and prevention of aphthous ulcers. OraDisc™ B is a mucoadhesive erodible disc containing 15 mg of benzocaine, developed for the treatment of oral pain.

ULURU also has its patented delivery strip for whitening teeth, which totally erodes - the OraDisc™ W- Erodible Whitening Strip for Teeth. This proprietary tooth whitening product comprises a laminated bilayer strip that uses the OraDisc™ technology.

Furthermore, the Company has its Altrazeal® product. ULURU developed and commercializes Altrazeal® - a transforming powder dressing with proprietary Nanoflex® technology, for the management of exuding wounds. Altrazeal® is a scientifically engineered advanced wound dressing designed to incorporate the desired features and benefits of the ideal wound dressing.

Altrazeal® has demonstrated potential clinical and economic advantages in numerous chronic and acute wounds. These include diabetic foot ulcers, venous leg ulcers, as well as geriatric wounds.

ULURU entered into a cooperation agreement with Saraya Co. Ltd. for the registration of Altrazeal® and further cooperation in Japan. Also, it entered into a licensing and distribution agreement with Juthis Corp. of South Korea. This agreement is for the marketing, sale, and distribution of Altrazeal® in Malaysia and South Korea.

Regarding ULURU’sNanoflex® Technology, it is a new class of material. The design of it is to optimize the wound bed environment and speed up healing. Altrazeal® is produced as a sterile powder. It is innovative in application and performance on a moist wound surface. Upon application to a moist wound, the powder interacts with wound exudate and hydrates. Hydration with exudate causes the powder to aggregate irreversibly and form a moist wound dressing that conforms to the surface of a wound bed and seals the wound.

ULURU, Inc. (ULUR), closed Thursday's trading session at $0.03385, even for the day. The average volume for the last 60 days is 21,398 and the stock's 52-week low/high is $0.03/$0.30.


The QualityStocks
Company Corner


Tapinator, Inc. (TAPM)

The QualityStocks Daily Newsletter would like to spotlight Tapinator, Inc. (TAPM). Today, Tapinator, Inc. closed trading at $0.1799, up 5.82%, on 37,622 volume with 13 trades. The stock’s average daily volume over the past 60 days is 73,260 and its 52-week low/high is $0.0711/$0.2419.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company that delivers a new generation of social communication solutions for business, today announces the online availability of its interview with New York-based mobile games developer and publisher, Tapinator, Inc. (OTCQB: TAPM). The interview can be heard at http://NNW.fm/TAPM-Interview-October-2017

Tapinator, Inc. (TAPM) is a developer and publisher of mobile games on the iOS, Google Play and Amazon platforms. The Company's portfolio includes over 300 mobile gaming titles generating hundreds of thousands of daily player downloads that provide predictable and attractive returns through the sale of branded advertisements and consumer app store transactions. Tapinator, based in New York and with product development teams located throughout the world, was founded in 2013 by a visionary team that has been building mobile games and applications since 2007 and has achieved multiple successful exits.

Tapinator's business strategy includes the creation of a select number of best-in-class Full-Featured Games, such as ROCKY™ and Solitaire Dash, which provide game players with more in-depth, unique content that supports long-term retention and generates higher investment returns. The Full-Featured Games model creates the potential for sustainable $100+ million franchise-type games that have product lifespans of at least five years. Tapinator uses a proprietary set of dynamic development and marketing processes factored upon gaming category, estimated player retention and projected player profitability.

Recent successful launches of two new Full-Featured titles – Big Sport Fishing 2017 and Dice Mage 2 – were recognized on the Apple iOS platform as "New Games We Love." During the game's first seven days after global release, Big Sport Fishing 2017 received well over 520,000 player downloads. Four new titles, ColorFill, Divide & Conquer, Shadowborne and Fusion Heroes, are in the pipeline for release in Q4 2017 and Q1 2018 as well. The formula for these game combines proven gameplay elements with best-in-class monetization systems, supplemented by Tapinator's strong creative team of developers, strategists and product specialists. The company's Rapid-Launch Games division also saw increasing player interest recently with the launch of Fidget Spinner Superhero and Scary Shark Evolution 3D.

Tapinator's diversified revenue sources includes 54 percent from advertising placed within its mobile games and 46 percent from consumer app store purchases. The Company limits advertising placements to between game levels and also runs rewarded video ad units that are tied directly into the game's currency. Tapinator's portfolio includes more than 300 active titles, with no single game accounting for more than 25 percent of total revenues during the first half of 2017.

As Tapinator looks toward the future, opportunities in Virtual Reality (VR) and Augmented Reality (AR) show great promise. The company has released several prototype VR games to gather data before pursuing a more significant VR product. Recent market reports suggest that the VR industry will hit $30 billion by 2020 and the AR industry will surpass that with a projected $120 billion. Tapinator also plans to pursue publishing transactions that leverage its network, platform relationships and operational excellence. Significant opportunities for expanding Tapinator's gaming IP to new platforms such as Steam and leading messaging apps are also on the horizon. The company is targeting a 30+ percent annual bookings growth target for 2017-2019. Disclaimer

Tapinator, Inc. Blog

Tapinator, Inc. News:

NetworkNewsWire Releases Exclusive Audio Interview with Tapinator, Inc. (TAPM)

Clowns to Haunt Mobile Phones for Halloween 2017 as Scary Clown: Halloween Night Goes Live on Google Play & Amazon App Store

NetworkNewsWire Announces Publication Discussing Competitive Companies in the Global Gaming Market

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.328, up 3.14%, on 504,855 volume with 234 trades. The stock’s average daily volume over the past 60 days is 509,113, and its 52-week low/high is $0.09/$0.72.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. The publication, titled, "Biotechs Develop Proprietary Systems to Drive CBD Research and Development," discusses biotech companies focused on the development of proprietary systems and procedures to drive research and production of cannabinoid pharmaceuticals. To view the full publication, visit: https://www.networknewswire.com/biotechs-develop-proprietary-systems-drive-cbd-research-development/

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

NetworkNewsWire Announces Publication Discussing Advanced Technology in Cannabinoid R&D

NetworkNewsWire Announces Publication on the Impact of Biosynthesis on Cannabinoid Pharmaceuticals

InMed Announces Positive Pre-Clinical Data on an Ocular Hydrogel Formulation using a Biosynthesized Cannabinoid

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.017954, up 2.59%, on 790,414 volume with 60 trades. The stock’s average daily volume over the past 60 days is 3,179,811, and its 52-week low/high is $0.0077/$0.04.

Global Payout, Inc. (GOHE) is pleased to announce that its majority owned subsidiary, MoneyTrac Technology, Inc. ("MTRAC", the "Company") is currently in the process of ramping-up sales and marketing efforts within Los Angeles County for its newly acquired brand, PotSaver. PotSaver will be releasing its premier Los Angeles publication on January 1st 2017 to coincide with the legalization of recreational use of cannabis in the most populous state in the country, California.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

Global Payout's MoneyTrac Technology, Inc. Ramps-Up Sales and Marketing Efforts in Los Angeles County for PotSaver Brand

Global Payout’s MoneyTrac Technology, Inc. Partners with Innovative Blockchain and Token Accelerator Pegasus Fintech, Inc. for Joint Development of Cryptocurrency-Based Token

Global Payout, Inc. is Finalizing Audit in Preparation for its Listing on the OTCQB Venture Marketplace.

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA). Today, Marijuana Company of America Inc. closed trading at $0.02427, up 1.97%, on 3,184,142 volume with 110 trades. The stock’s average daily volume over the past 60 days is 4,455,964 and its 52-week low/high is $0.0181/$0.1985.

Marijuana Company of America (OTC: MCOA) is a unique corporation with a strategic business structure that functions as an umbrella, bringing together a diverse portfolio of investments and joint ventures within the legal cannabis industry. For companies like MCOA, the path forward is clear – participation in the legal cannabis and hemp industries makes investment sense (http://nnw.fm/P6De1). MCOA provides multiple opportunities for investors through turn-key services and its branded hempSMART™ cannabinoid product line, which is sold via an affiliate marketing program.

Marijuana Company of America Inc. (MCOA) (the "Company") are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA's CEO, founded the first marijuana company ever to trade on a US stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing expotentially and consequently the founders of MCOA have contructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can also be used to produce products that are carbon neutral or even carbon negative, like the longest, strongest natural fiber on earth, building materials that are mold, pest and fire proof, super foods and so much more for additional business opportunities. No part of the plant is left unused and the Company's overall stategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented exponential growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015's $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal and cannabis and industrial hemp sectors. The Company's business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA's strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product "hempSMART Brain," is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience. Disclaimer

Marijuana Company of America Inc. Blog

Marijuana Company of America Inc. News:

Marijuana Company of America (MCOA) Delivers with Unique Marketing, Distribution Platforms

Marijuana Company of America Engages NetworkNewsWire for Corporate Communications Solution

Marijuana Company of America and Global Hemp Group to Form Joint Venture With Space Cowboys' Colorado Farm

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0596, even for the day, on 1,577,996 volume with 160 trades. The stock’s average daily volume over the past 60 days is 16,600,111, and its 52-week low/high is $0.008/$0.415.

Investorideas.com, a global news source covering leading sectors including cannabis and bitcoin, releases the second of a two-part podcast interview with Wil Ralston of SinglePoint, Inc. (OTC PINK: SING). SinglePoint's Bitcoin exchange is nearly ready to launch according to company President Wil Ralston. Listen to the podcast here: http://www.investorideas.com/Audio/Podcasts/102517-WilRalston-Cryptocurrency.mp3

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

Podcast Series with Wil Ralston of SinglePoint Talking about Acquisitions, Cannabis and Developments in Cryptocurrency

CannabisNewsWire Announces Publication Highlighting Investment Opportunities in Cryptocurrency

SinglePoint and AppSwarm Sign LOI to Launch Cannabis-Focused Applications

Grey Cloak Tech, Inc. (GRCK)

The QualityStocks Daily Newsletter would like to spotlight Grey Cloak Tech, Inc. (GRCK). Today, Grey Cloak Tech, Inc. closed trading at $0.014, off by 6.67%, on 15,840,695 volume with 316 trades. The stock’s average daily volume over the past 60 days is 4,396,441 and its 52-week low/high is $0.0091/$0.35.

Grey Cloak Tech Inc. (OTCQB: GRCK) announced today that its Board of Directors has decided to abandon and cancel the reverse stock split that was approved by the Board of Directors and the Company's shareholders in February 2017. On February 23, 2017, the Company held a special shareholder meeting to vote on whether to amend our Articles of Incorporation to effect a reverse stock split of our common stock at a ratio of up to 1-for-100, among other proposals. The reverse split was approved as set forth in our proxy statement dated February 1, 2017, giving our Board of Directors complete discretion to set the ratio and timing of the reverse stock split at a future date but no later than December 31, 2017.

Grey Cloak Tech, Inc. (OTCQB: GRCK), a Las Vegas, Nevada-based company, aims to expand into the rapidly growing cannabinoid (CBD) market through the pending acquisition of Eqova Life Sciences, which focuses on providing a full spectrum line of clinical-grade hemp oil (CBD) products to the medical practitioner market. Eqova Life Sciences, based in Denver, Colorado, develops its own high quality, branded product line of hemp oil health products, with the offer of producing private labels to qualified partners.

Eqova Life Sciences recently exhibited the company's CBD products at the Integrative Medicine Summit in Denver, Colorado, which was attended by over 200 medical professionals. As part of the exhibition, Eqova Life Sciences also debuted its new CannaBio Salve, an innovative topical salve infused with several aromatic natural oils. The company's formulations combine the scientifically-validated, powerful benefits of cannabinoids in standardized products which are then distributed to patients under the care of qualified health practitioners. All Eqova products are carefully researched and go through rigorous third-party testing before and after marketing, providing the security of a clinical-grade product made in cGMP Compliant Labs located in the United States.

According to The Hemp Business Journal, the CBD products marketplace is projected to grow 700 percent by 2020 with annual sales reaching $2.1 billion. The purchase of Eqova Life Sciences would be a natural fit for the company, which has been looking for a way to build shareholder value by adding acquisitions from the rapidly growing CBD sector. Grey Cloak Tech believes medical practitioners seeking high-quality CBD products represent a vastly underserved market. To date, no other hemp oil company has exclusively focused on providing clinical-grade, full-spectrum hemp oil products to this important segment of the medical community.

Grey Cloak Tech also develops advanced software to overcome costly digital threats, most commonly known as online fraud. Grey Cloak Tech leads the industry with continuous development of the most comprehensive and effective weapons against online security threats. The company's proprietary digital advertising fraud detection software, Fraudlytic, provides a cloud-based, secure platform that monitors Internet traffic in real time, blocking malicious and false clicks, while allowing real consumers to view offers and make purchases. Disclaimer

Grey Cloak Tech, Inc. Blog

Grey Cloak Tech, Inc. News:

Grey Cloak Tech Clarifies Reverse Split

Grey Cloak Tech Completes Acquisition of Eqova Life Sciences

Grey Cloak Tech Commences Trading on the OTCQB Venture Market

Kootenay Zinc Corp. (CSE:ZNK) (OTCQB:KTNNF)

The QualityStocks Daily Newsletter would like to spotlight Kootenay Zinc Corp. (KTNNF). Today, Kootenay Zinc Corp. closed trading at $0.0429, up 15.95%, on 20,100 volume with 6 trades. The stock’s average daily volume over the past 60 days is 19,387, and its 52-week low/high is $0.007/$0.59.

Kootenay Zinc Corp. (KTNNF) is a mineral exploration and development company focused on discovering large-scale sedimentary-exhalative ("SEDEX") zinc deposits. Based in Vancouver, British Columbia, the company is ideally positioned near its primary target, the Sully Property, located 18 miles east of the world-class Sullivan Mine.

Of the 22 raw materials tracked by the Bloomberg Commodity Index, zinc was the best-performing base metal in 2016. Based on a widening global supply deficit, outlook for the commodity remains strong. As the most closely tied base metal to the Chinese economy, zinc demand and prices are expected to rise well into the year 2020, putting increased pressure on zinc supply.

For 2017, Goldman Sachs has predicted a 360,000 ton shortage of zinc, along with a subsequent rise in zinc prices to $2,500 per metric ton in the first half of the year. Zinc continues to make history in the metals exchange, driving significant interest in the market amid supply constraints in concentrates and refined metal drive prices.

Ready to claim its share of the market, Kootenay Zinc is focused on its Sully Property. It comprises 1,375 hectares and overlies rocks of similar age and origin as those which host the legendary Sullivan deposit. The Sullivan mine was discovered in 1892, and is known to be one of the world's largest SEDEX deposits. Over its 100-year lifetime, Sullivan produced approximately 150 million tonnes of ore, including approximately 300 million ounces of silver, 8 million tonnes of zinc and 8 million tonnes of lead.

Notably, geophysical data suggests that Kootenay Zinc's Sully project and Sullivan share many geological features:

  • Strata at Sully are in the same sedimentary basin as the Sullivan mine
  • The exact stratigraphic time horizon at which Sullivan formed is present at Sully
  • Filtered AeroMag anomalies coincident with Sullivan Time at Sully appear similar to Sullivan
  • Gravity anomaly at Sully indicates excess mass of comparable magnitude to Sullivan
  • Pb-Zn is present as traces in outcrop, drill core and in a soil geochemical anomaly

The squeeze in zinc supplies particularly affects China, which is both the world's largest zinc consumer and its largest producer, with 4.9 million tons of output in 2015. Chinese manufacturers are now being forced to import zinc for use in cars, household appliances, paints, rubber products and smartphones.

Zinc's rally shows no sign of slowing down in the near future, and companies that currently occupy stake in a zinc deposit find themselves in an enviable position over miners rushing to find new reserves. With its Sully Project, Kootenay Zinc could be on track to capture its share of the market, guided by a management team of mining directors and executives that currently lead some of the world's best mining companies and have been involved in world-class discoveries which sold for billions of dollars. The company's technical team includes industry experts that have worked on mega-mining projects, including the Sullivan and Voisey Bay projects. Disclaimer

Kootenay Zinc Corp. Company Blog

Kootenay Zinc Corp. News:

Sully Project - E3 Target Drilling Underway

Kootenay Zinc Corp.: Sully Project Exploration Update

NetworkNewsWire Releases Exclusive Audio Interview with Kootenay Zinc Corp. (KTNNF)


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(INND) +150.00%


Trader Power News
(NEOS) +37.67%


MarketClub Analysis
(VISI) +20.59%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251